Live Chat

Berdagang Vir Biotechnology VIR

Jual
 Beli

VirBiotechnology carta live

5m 15m 30m 1h 4h 1d 1w

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

Berita Terkini

Frances Wang 2024 Nov 20, 16:00

MicroStrategy Stock Surges as Bitcoin price rises to fresh record above $94K

Cryptocurrencies
Frances Wang 2024 Nov 20, 16:00

Nasdaq futures decline, Nvidia shares dip following the earnings report

Indices CFD Trading Stocks
Mixed market performance
Neil Wilson 2024 Nov 20, 16:00

Markets Mixed Amid Inflation, Tech Rally, and UK Economic Woes

USD Tech S&P 500
Frances Wang 2024 Nov 19, 16:00

Nvidia shares rallied on AI spending ahead of Nvidia Q3 earnings 2024

NVDA Stocks
Frances Wang 2024 Nov 19, 16:00

Bitcoin price hits record high over $93,800 as Trump rally resumes

Cryptocurrencies
Rising gold prices
Neil Wilson 2024 Nov 19, 16:00

Gold Shines, Bitcoin Surges, and Nvidia Earnings in Focus

Gold Cryptocurrencies
Frances Wang 2024 Nov 18, 16:00

What is the cryptocurrency market doing: Musk's DOGE Role Boosts Dogecoin

Cryptocurrencies
Frances Wang 2024 Nov 18, 16:00

Bitcoin price prediction: BTC May Reach $100K Before New Year

Cryptocurrencies

Maklumat

Sebaran nilai

0.05

Spread (%)

0.7429 %

Leveraj

1:5

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Khamis

14:31 - 20:59

Isnin

14:31-20:59

Selasa

14:31-20:59

Rabu

14:31-20:59

Jumaat

14:31-20:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

954399552

Saham Tertunggak

137720000

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-3.87

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumen Berkaitan

Aset
Jual
Beli
Perubahan (%):

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang
Instrumen Berkaitan
Trustpilot
Live Chat